FDA Panel Narrowly Rejects One Peptide for Compounding, Approves Two Others

An FDA advisory panel voted narrowly against allowing compounding of one peptide while supporting the compounding of two others, addressing growing interest in peptide therapies. Peptides are short chains of amino acids increasingly used in clinical settings, with some public figures like Robert F. Kennedy Jr. promoting their use. The panel's mixed decision reflects ongoing debates about peptide safety, efficacy, and appropriate regulatory pathways. This ruling impacts patients seeking peptide-based treatments and highlights the FDA's cautious approach to compounded medications. The decision underscores the need for continued research and evidence to support peptide therapies in clinical practice.